Hereditary Angioedema Market Report
Hereditary Angioedema Market Trends, Dynamics & Market Insights See less
Hereditary Angioedema Market Trends, Dynamics & Market Insights
Hereditary Angioedema Market, By Drug Class (C1 Esterase Inhibitor, Kallikrein Inhibitor, Selective Bradykinin B2 Receptor Antagonist), Route of Administration (Intravenous, Subcutaneous Injection, Oral), End-Use (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), and Region - COVID-19 Impact Analysis and Forecast to 2026.
This market research report provides in-depth information on trends, dynamics, revenue opportunities, competitive landscape, and recent developments in the global Hereditary Angioedema market. The historic years considered for the study are 2016-2019, the base year is 2020, the estimated year is 2021, and the forecast period is 2022-2026.
Hereditary Angioedema Market, By Drug Class (C1 Esterase Inhibitor, Kallikrein Inhibitor, Selective Bradykinin B2 Receptor Antagonist), Route of Administration (Intravenous, Subcutaneous Injection, Oral), End-Use (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), and Region ...
The Hereditary Angioedema Market is projected to grow from USD 1.9 billion in 2020 to USD 2.8 billion by 2026 at a CAGR of around 7.2% during the forecast period.
Hereditary angioedema is a genetic disorder characterized by persistent episodes of severe swelling (angioedema). It most commonly affects limbs, intestinal tract, face, and airway. It can be classified into three types based on genetic defects such as type I HAE with low levels of C1-INH in the body, type II with poorly functioning C1-INH, or the recently identified types of HAE with normal functioning C1-INH (formerly known as type III HAE).
Key players operating in the Hereditary Angioedema market are-
The growth of the hereditary angioedema market is primarily driven by rising incidences of hereditary angioedema across geographies. Growing emphasis on initiatives aimed at creating awareness among consumers related to the disease is expected to augment the market growth substantially. In addition to this, increasing investment in research and development activities to develop a novel drug is likely to create lucrative opportunities for the players operating in the global hereditary angioedema market in the coming years.
By end-use, the hereditary angioedema market has been bifurcated into retail pharmacies, hospital pharmacies, and online pharmacies. The hospital pharmacies segment accounted for the largest market share in 2020 and is projected to register significant growth during the review period. The segment can be attributed to the convenience and availability of drugs.
By region, the North American market accounted for the largest market share in 2020 and is projected to grow at a robust CAGR during the review period. This can be attributed to expanding geriatric populace and increasing investment in R&D activities to develop new drugs coupled with the presence of key market players such as Shire plc (US) and BioCryst Pharmaceuticals, Inc. (US). The market growth in Asia-Pacific is expected to be driven by an increasing number of people having hereditary angioedema disease.
The covid-19 outbreak posed significant challenges across verticals worldwide. It impacted the growth of the hereditary angioedema market negatively as the diagnostic procedures other than covid-19 treatment declined due to fear of coronavirus infection. Also, supply chain disruptions due to the imposition of lockdown affected the product availability on time and thus, affected the market growth.
Here is the list of the group of customers that the hereditary angioedema market hopes to have the greatest opportunity to convert-
Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at firstname.lastname@example.org.
The hereditary angioedema market is expected to witness an impressive growth of 7.2% CAGR in the coming years.
Pharming Group NV (Netherlands), Shire plc (US), CSL Limited (Australia), iBio Inc. (US), Bio-Cryst Pharmaceuticals, Inc. (US), Ionis Pharmaceuticals (US), Sanofi S.A. (France), Attune Phar-maceuticals, Inc. (US) and Adverum Biotechnologies, Inc. (US) are among the key players in the hereditary angioedema market.
The hereditary angioedema market size is expected to reach USD 2.8 billion in the foreseeable future.
The hospital pharmacies segment is expected to register significant growth in the hereditary angioedema market in the coming years.
North America accounted for the largest share in the hereditary angioedema market in 2020.
Hereditary angioedema distributors, Hereditary angioedema suppliers, Hereditary angioedema manufacturers, Logistics organizations, Government bodies are the target audience in the hereditary angioedema market.